Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to 
Treat Liver Cancer 
Expands the Company's Patent Portfolio in Oncology Therapeutics 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 11/07/13 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces receipt
of a Notice of Allowance from the U.S. Patent and Trademark Office
(USPTO) related to U.S. Patent Application No. 13/481,105 titled
"Targeting microRNAs for the Treatment of Liver Cancer." 
This allowance is for a therapeutic patent that protects a method for
treating hepatocellular carcinoma (HCC), or liver cancer, and covers
the administration of a compound comprising a modified
oligonucleotide that is an anti-miR-222. In addition, various
modifications of the nucleotide are claimed. There is an additional
claim which refers to the reduction of the levels of serum
alpha-fetoprotein or serum des-gamma-carboxyprothrombin in the
subject to be treated.  
"HCC is the fifth most common cancer in the world and the third
leading cause of cancer deaths. Because standard chemotherapy usually
has no beneficial outcome on HCC patients, there is significant need
for new therapeutic modalities and novel therapeutic targets in order
to develop more effective treatments for HCC," said E. Robert
Wassman, M.D., Chief Medical Officer of Rosetta Genomics. "Since
microRNAs are master regulators of gene expression, their
de-regulation can trigger changes that lead to the disease phenotype,
and the modulation of their activity can be a key to the development
of novel therapies."  
"We continue to fortify and protect our global leadership position in
microRNA technology with the addition of this valuable patent
allowance," commented Kenneth A. Berlin, President and CEO of Rosetta
Genomics. "Our solid patent position in microRNAs provides us with
the opportunity to license, partner or otherwise derive value from
this powerful technology for use in a variety of diagnostic and
targeted therapeutics in oncology where there continues to be a
large, unmet medical need." 
Rosetta Genomics maintains an active intellectual property strategy
to protect its leadership position in microRNA technology. Rosetta's
portfolio includes 33 issued patents, including 30 in the U.S. In
addition, Rosetta has 43 patent applications pending, of which 23 are
in the U.S. These applications protect the specific microRNAs used in
the Company's products and cover composition of matter, diagnostic
applications, therapeutic applications and discovery process
applications for microRNAs in humans. 
About Liver Cancer
 According to the National Cancer Institute,
primary liver and bile duct cancers are the fifth most common cause
of cancer death in men and the ninth most common cause of cancer
death in women. Over the past two decades, the incidence rates for
these cancers have increased in people of all races and in both
genders; mortality rates have increased in all groups except
Asians/Pacific Islanders. Men are more than twice as likely as women
to develop and die from liver and bile duct cancers, and African
Americans and Hispanics are almost twice as likely to develop these
cancers as whites. Although Hispanics and Asians/Pacific Islanders
have lower incidence rates of most types of cancer than whites, they
have much higher rates of liver cancer. 
Liver cancer is closely associated with hepatitis virus infections.
Almost all cases of liver cancer in the United States occur in people
who first had cirrhosis, usually resulting from hepatitis B or C
infection or from heavy alcohol use. Ingestion of foods contaminated
with aflatoxin and obesity may also increase liver cancer risk.
Vaccinating for hepatitis B provides long-term protection from
hepatitis B infection and has been shown to lower the risk of liver
cancer in children, although it is not yet known whether it lowers
the risk in adults. There is no standard or routine screening test
for liver cancer. Standard treatments for liver cancer include
surgery, radiation therapy, chemotherapy, percutaneous ethanol
injection and targeted therapy. 
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test(TM), Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test(TM), Rosetta's
development of personalized medicine products and services, Rosetta
licensing, partnering or otherwise deriving value from microRNA
technology for use in a variety of diagnostic and targeted
therapeutics and Rosetta developing therapeutic products., constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(609) 419-9000, ext. 1326 
Investor Contacts: 
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.